Leading Bangalore Hospital CEOs Convene for Masimo Roundtable
BANGALORE, India - Tuesday, January 3rd 2017 [ME NewsWire]
(BUSINESS
WIRE)-- Masimo (NASDAQ: MASI) announced today the launch and
availability of the Rad-97™ Pulse-CO Oximeter®* and Next Generation
SedLine®* Brain Function Monitoring in India. The announcement was made
in Bangalore by Joe Kiani, Founder and CEO of Masimo, at a roundtable of
the CEOs of top Bangalore hospitals.
Joe Kiani, Founder and CEO,
Masimo, commented, “The Indian healthcare sector recognizes the need
for technologies that help their clinicians get the best results, the
first time. Masimo’s noninvasive patient monitoring technology
innovations offer capabilities that have never been possible before.
With a large population and a burgeoning demand for an improved quality
of life – including the safe, high-quality healthcare to which all are
entitled – India continues to be a focus market for Masimo. We will
continue to invest in India and strive to make our technologies and
products as accessible as possible, as evidenced by the new Rad-97 and
Next Generation SedLine.”
Bharat Monteiro, Masimo Country Manager
for India, noted, “Masimo is committed to doing what is best for
patient care in India. In the course of our engagement with leading
Indian hospitals, we have witnessed an increased awareness of and
commitment to patient safety requirements. Medical providers across the
country are eager to adopt advanced technologies and monitoring devices,
such as Rad-97 and Next Generation SedLine, which we hope will help
provide access to better healthcare, at lower cost.”
Dr. Ashutosh
Raghuvanshi, Managing Director and Group CEO of Narayana Health
Hospitals, one of the participants in the roundtable, commented, “We
constantly endeavor to improve the facilities at our hospitals to ensure
better patient care and treatment outcomes. With the newly launched
Rad-97, we will be able to use Masimo SET® pulse oximetry in more care
areas, including ward monitoring, which will help facilitate better
monitoring and patient treatment. Narayana Health performs the highest
number of cardiac surgeries in India, and I believe that noninvasive
hemoglobin (SpHb) will add immense value to complex cardiac surgeries,
helping us reduce unwarranted transfusions and the risk of infection.”
Rad-97
features Measure-through Motion and Low Perfusion™ SET® pulse oximetry,
which studies have shown helps clinicians reduce severe retinopathy of
prematurity in neonates,1 improve CCHD screening in newborns,2 and, when
used for continuous monitoring in post-surgical wards, reduce rapid
response activations and costs.3,4,5 Rad-97 also offers the same
upgradeable rainbow SET™ technology as the Radical-7® Pulse CO-Oximeter,
in a versatile, standalone monitor configuration. Using Rad-97,
clinicians can monitor such rainbow® measurements as total hemoglobin
(SpHb®) and PVi®. Studies with SpHb have shown reductions in unnecessary
blood transfusion†,6,7 and when used with PVI, reductions in length of
hospital stay8 and 30- and 90-day mortality.9 rainbow® can also measure
methemoglobin (SpMet®), acoustic respiration rate (RRa®),
carboxyhemoglobin (SpCO®), Oxygen Reserve Index™* (ORi™), and oxygen
content (SpOC™). Rad-97 also features an integrated camera* for
clinician tele-presence via Patient SafetyNet™‡ and a high-resolution
1080p HD color display with user-friendly multi-touch navigation,
similar to Root® and Radical-7, allowing clinicians to easily customize
the device to best suit their monitoring needs.
SedLine features
four simultaneous EEG leads to enable continuous assessment of both
sides of the brain, as well as a Density Spectral Array (DSA), an
easy-to-interpret, high-resolution display of bi-hemispheric activity.
Next Generation SedLine enhances Masimo’s processed EEG parameter, the
Patient State Index (PSI), to make it less susceptible to
electromyographic (EMG) interference and to improve performance in
low-power EEG cases.
@MasimoInnovates | #Masimo
*Rad-97, the camera feature, Next Generation SedLine, and ORi do not have 510(k) clearance and are not available in the U.S.
†Clinical
decisions regarding red blood cell transfusions should be based on the
clinician’s judgment considering, among other factors: patient
condition, continuous SpHb monitoring, and laboratory diagnostic tests
using blood samples.
‡The use of the trademark SafetyNet is under license from University HealthSystem Consortium.
References
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2 Technology. Acta
Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al.
Impact of pulse oximetry screening on the detection of duct dependent
congenital heart disease: a Swedish prospective screening study in
39,821 newborns. BMJ. 2009;338.
Taenzer AH et al. Impact of Pulse
Oximetry Surveillance on Rescue Events and Intensive Care Unit
Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010;
112(2):282-287.
Taenzer AH et al. Postoperative Monitoring – The
Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring
Management for General Care Units: Strategy, Design, and Implementation.
The Joint Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
Ehrenfeld JM et al. Continuous Non-invasive
Hemoglobin Monitoring during Orthopedia Surgery: A Randomized Trial. J
Blood Disorders Transf. 2014. 5:9. 2.
Awada WN et al. Continuous
and noninvasive hemoglobin monitoring reduces red blood cell transfusion
during neurosurgery: a prospective cohort study. J Clin Monit Comput.
2015 Feb 4.
Thiele RH et al. Standardization of Care: Impact of
an Enhanced Recovery Protocol on Length of Stay, Complications, and
Direct Costs after Colorectal Surgery. JACS (2015). doi:
10.1016/j.jamcollsurg.2014.12.042.
Nathan N et al. Impact of
Continuous Perioperative SpHb Monitoring. Proceedings from the 2016 ASA
Annual Meeting, Chicago. Abstract #A1103.
About Masimo
Masimo
(NASDAQ: MASI) is a global leader in innovative noninvasive monitoring
technologies. Our mission is to improve patient outcomes and reduce the
cost of care by taking noninvasive monitoring to new sites and
applications. In 1995, the company debuted Masimo SET® Measure-through
Motion and Low Perfusion™ pulse oximetry, which has been shown in
multiple studies to significantly reduce false alarms and accurately
monitor for true alarms. Masimo SET® is estimated to be used on more
than 100 million patients in leading hospitals and other healthcare
settings around the world. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently,
Pleth Variability Index (PVi®) and Oxygen Reserve Index (ORi™), in
addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and connectivity
platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com. All published clinical studies on Masimo
products can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This
press release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities
Litigation Reform Act of 1995. These forward-looking statements include,
among others, statements regarding the potential effectiveness of
Masimo Rad-97™ Pulse CO-Oximeter® and Next Generation SedLine® Brain
Function Monitoring. These forward-looking statements are based on
current expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and many
of which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo Rad-97 and SedLine, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide comparable accuracy and unique
advantages; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do not
know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in
their entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a
result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
Contacts
Masimo in India
Adfactors PR
Ajith Pai / Amrutha Moorthy
+91 96633 94732
ajit.pai@adfactorspr.com / amrutha.moorthy@adfactorspr.com
or
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com
Permalink: http://me-newswire.net/news/19288/en
Sagemcom Unveils Its Next Generation Fiber, Wi-Fi Media Gateway, 4K UHD HDR Set-Top Boxes and Its End-to-End Solution for IOT
